SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

NCT06288893 | Not Yet Recruiting Phase 2

• 1 other identifier: DEU-2001
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets

Conditions

COVID-19

Keywords

SHEN211 tablets; multicenter phase II clinical study; efficacy; safety and pharmacokinetics

Outcome Measures

Primary Outcomes (1)

• Change from baseline in SARS-CoV-2 viral load at each time point

  Change from baseline in SARS-CoV-2 viral load at each time point

  Up to day 28

Secondary Outcomes (10)

• Time of recovery

  Up to day 28

• Time to response

  Up to day 28

• Time to negative

  Up to day 28

• Percentage of subjects with disappearance of clinical symptoms

  Up to day 28

• Change in COVID-19 symptom score

  Up to day 28

Study Arms (2)

SHEN211 Tablets

ACTIVE COMPARATOR

A total of 20 subjects were randomized to the test group

Drug: SHEN211 Tablets

Placebo for SHEN211 Tablets

PLACEBO COMPARATOR

10 subjects randomized to placebo

Procedure: Placebo for SHEN211 Tablets

Interventions

SHEN211 Tablets DRUG

SHEN211 tablets, participants will receive 330 mg (3 tablets) QD (once a day) on Day 1 and 110 mg (1 tablet) SHEN211 tablets QD orally on Days 2-5.

Also known as: Test group

SHEN211 Tablets

Placebo for SHEN211 Tablets PROCEDURE

Placebo tablets, participants will receive 3 tablets QD (once daily) on Day 1 and 1 tablet QD orally on Days 2-5

Also known as: control group

Placebo for SHEN211 Tablets

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• subjects must be 18 years of age or older at the time of signing the informed consent form;
• subject has a positive SARS-CoV-2 test result;
• Subjects have one or more mild and moderate COVID-19 clinical symptoms with a symptom score of ≥ 2 (see Attached Table 2): fever, cough, sore throat or dry throat, nasal congestion or runny nose, fatigue or fatigue, headache, muscle or body pain (or soreness), shortness of breath or dyspnea, nausea, vomiting, diarrhea; Presence of one or more of the following signs/symptoms within 24 hours prior to randomization: fever, cough, sore throat or dry throat, nasal congestion or runny nose, fatigue or fatigue, headache, muscle or body aches (or aches), shortness of breath or dyspnea, nausea, vomiting, diarrhea;
• subjects need to meet conditions: 1) The first occurrence of COVID-19 symptoms ≤ 3 days from the first administration of investigational product; 2) Samples for the first positive SARS-CoV-2 virus infection assay were ≤ 5 days from the first administration of investigational product; 3) SARS-CoV-2 viral nucleic acid detection Ct value ≤ 30 on the day of the first dose;
• Subjects (women and men of childbearing age) and their sexual partners are willing to have no fertility plan and voluntarily take effective contraceptive measures and have no sperm donation or egg donation plan from the signing of the informed consent form to 1 month after the last dose of the study drug (see Appendix 6 for the definition and contraceptive measures of women of childbearing age);
• The subject is able to understand and abide by the procedures and methods of this clinical trial. After full informed consent, the subject voluntarily participates and signs the informed consent form by himself/herself, or has a legal representative who can provide the informed consent form.

You may not qualify if:

• subjects may progress to severe and severe COVID-19 before randomization as judged by the investigator;
• SpO2 ≤ 93% or PaO2/FiO2 ≤ 300 mmHg, or respiratory rate ≥ 30/minute on sea-level room air;
• urgent or expected need for nasal high-flow oxygen therapy or noninvasive positive pressure ventilation, invasive mechanical ventilation, or ECMO;
• known history of active hepatitis (acute or chronic active hepatitis B or C), cirrhosis, or hepatic decompensation (including ascites, variceal bleeding, or hepatic encephalopathy); impaired immune system (including patients who have been treated with immunosuppressive agents for a long time, or patients with progressive or recurrent cancer, or known human immunodeficiency virus infection);
• Screening ALT or AST \> 1.5 times ULN or Cockcroft-Gault defined known current renal impairment as CrCl \< 30 mL/min or requiring dialysis (see Appendix 4 for calculation formula);
• Subjects who have received antiviral drugs (e.g., neltamivir tablets/ritonavir tablets, azvudine tablets, monoprevir capsules, sinotervir tablets/ritonavir tablets, deuterated remidavir hydrobromide tablets, and Chinese herbal medicine/Chinese patent medicine for anti-coronavirus therapy) treatment or prevention within 30 days before randomization;
• The subject has received SARS-CoV-2 monoclonal antibody therapy or prophylaxis or antiviral therapy (including study treatment) or the subject has received convalescent COVID-19 plasma therapy;
• the subject has a history of dysphagia or gastrointestinal disease that seriously affects drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, subtotal gastrectomy, etc.);
• acute attack of chronic respiratory diseases, including bronchial asthma, chronic obstructive pulmonary disease;
• concurrent influenza at screening, which may interfere with the assessment of response to study intervention based on symptoms, signs, laboratory tests, or imaging indicating a high likelihood of bacterial infection;
• received any COVID-19 vaccine within 3 months before randomization, or infected with novel coronavirus within 3 months before randomization;
• Complications requiring surgery before randomization or throughout the study period and major surgery 14 days before randomization, or life-threatening complications within 30 days before randomization as considered by the investigator;
• Use of the following drugs within 14 days before enrollment: strong cytochrome P453A (CYP3A) inhibitors, strong CYP3A inducers, products containing St. John 's wort (Hypericum perforatum);
• Participated in other clinical trials or taking experimental drugs within 3 months before randomization;
• known hypersensitivity to any component used in the formulation of the intervention drug;

Sponsors & Collaborators

• JKT Biopharma Co., Ltd.: lead

Study Sites (1)

Shenzhen Third People 's Hospital

Shenzhen, Guangdong, 518112, China

Location

MeSH Terms

Conditions

COVID-19

Interventions

Control Groups

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic Research Design; Epidemiologic Methods; Investigative Techniques; Research Design; Methods

Study Officials

• Hongzhou Lu, ph.D

  Shenzhen Third People 's Hospital

  PRINCIPAL INVESTIGATOR

• Rui Song

  Beijing Ditan Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hongzhou Lu, ph.D

CONTACT

0755-61232898; luhongzhou@fudan.edu.cn

Ximin Meng

CONTACT

0755-61238920; szywjd2015@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: double-blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Randomized 2:1 to experimental and placebo arms

Study Record Dates

• First Submitted: February 29, 2024
• First Posted: March 1, 2024
• Study Start: April 1, 2024
• Primary Completion: August 1, 2024
• Study Completion: January 1, 2025
• Last Updated: March 4, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)